Mirae Asset Global Investments Co. Ltd. Purchases 2,785 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Mirae Asset Global Investments Co. Ltd. increased its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 12.6% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 24,941 shares of the medical equipment provider's stock after buying an additional 2,785 shares during the quarter. Mirae Asset Global Investments Co. Ltd.'s holdings in Zimmer Biomet were worth $2,800,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also bought and sold shares of ZBH. Garde Capital Inc. bought a new stake in shares of Zimmer Biomet in the 1st quarter worth approximately $29,000. Menard Financial Group LLC bought a new position in shares of Zimmer Biomet during the 4th quarter valued at $30,000. Accredited Wealth Management LLC purchased a new position in Zimmer Biomet in the 4th quarter worth $36,000. OFI Invest Asset Management bought a new stake in Zimmer Biomet in the fourth quarter worth $40,000. Finally, FNY Investment Advisers LLC boosted its position in Zimmer Biomet by 90.5% during the first quarter. FNY Investment Advisers LLC now owns 400 shares of the medical equipment provider's stock valued at $45,000 after buying an additional 190 shares during the period. Hedge funds and other institutional investors own 88.89% of the company's stock.

Insider Buying and Selling

In other news, insider Sang Yi sold 1,000 shares of the company's stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $95.00, for a total value of $95,000.00. Following the sale, the insider directly owned 20,424 shares of the company's stock, valued at $1,940,280. This represents a 4.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 1.39% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Royal Bank Of Canada lowered their target price on Zimmer Biomet from $125.00 to $112.00 and set an "outperform" rating for the company in a research note on Tuesday, May 6th. Wells Fargo & Company decreased their price target on Zimmer Biomet from $113.00 to $98.00 and set an "equal weight" rating on the stock in a research note on Tuesday, May 6th. Stifel Nicolaus set a $115.00 price objective on Zimmer Biomet and gave the company a "buy" rating in a research report on Tuesday, May 6th. BTIG Research restated a "buy" rating on shares of Zimmer Biomet in a report on Monday, April 14th. Finally, Canaccord Genuity Group lowered their price target on shares of Zimmer Biomet from $115.00 to $101.00 and set a "hold" rating for the company in a report on Monday, May 12th. Two analysts have rated the stock with a sell rating, ten have given a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $111.33.

Zimmer Biomet Trading Up 0.2%

Shares of ZBH traded up $0.17 during trading hours on Friday, reaching $93.67. 927,032 shares of the company traded hands, compared to its average volume of 1,808,334. Zimmer Biomet Holdings, Inc. has a 12 month low of $89.22 and a 12 month high of $116.71. The company has a quick ratio of 1.46, a current ratio of 2.44 and a debt-to-equity ratio of 0.53. The company's fifty day moving average price is $94.04 and its two-hundred day moving average price is $101.78. The company has a market capitalization of $18.53 billion, a price-to-earnings ratio of 20.72, a price-to-earnings-growth ratio of 2.17 and a beta of 0.71.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.04. Zimmer Biomet had a return on equity of 12.73% and a net margin of 11.86%. The business had revenue of $1.91 billion for the quarter, compared to analysts' expectations of $1.89 billion. During the same period in the previous year, the firm posted $1.94 EPS. The business's revenue was up 1.1% on a year-over-year basis. Equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Thursday, June 26th will be issued a $0.24 dividend. The ex-dividend date of this dividend is Thursday, June 26th. This represents a $0.96 dividend on an annualized basis and a yield of 1.02%. Zimmer Biomet's dividend payout ratio (DPR) is 21.24%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.